Add BrightSurf on Google Email

Your nose is a battlefield

Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.

SourceLa Jolla Institute for Immunology·JournalScience Translational Medicine·TypeExperimental study·DateApr 29, 2026

European Immunization Week 2026, For every generation, vaccines work: three countries reach 90% HPV vaccination target as Europe steps up action on cancer prevention

Three European countries reach 90% HPV vaccination coverage among girls by age 15, marking progress in cervical cancer prevention. HPV vaccination programmes show significant reductions in infections and precancerous lesions, with early administration increasing full protective potential.

Extend vaccination opportunities and involve community members in communicating about vaccines to boost uptake, say researchers

Researchers found that extending vaccination opportunities, involving community members, and providing financial incentives are effective ways to increase vaccine uptake. The study analyzed international trial evidence and highlighted the most effective components across different populations and contexts.

SourceBMJ Group·JournalThe BMJ·TypeMeta-analysis·DateApr 15, 2026

Influenza vaccine could protect against heart attack and stroke even among people who get infected

Researchers found that influenza vaccination reduced the risk of heart attack and stroke by half for those who got infected, even if they didn't get vaccinated beforehand. The study's findings suggest prioritizing influenza vaccination among high-risk populations could have significant public health impact.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeNews article·DateApr 2, 2026

Johns Hopkins team develops therapeutic, nasally delivered DNA vaccine for tuberculosis

The Johns Hopkins team developed a therapeutic intranasal DNA vaccine against tuberculosis that accelerated disease clearance, improved treatment outcomes, and stimulated immune responses. The vaccine combines two genes to direct the immune system to fight drug-tolerant bacterial persisters, showing promise for treating TB.

SourceJohns Hopkins Medicine·JournalJournal of Clinical Investigation·DateApr 1, 2026

HPV vaccination uptake in adults shaped by knowledge and medical advice

A nationwide survey in Switzerland found that HPV vaccination uptake among adults was lower than among adolescents, with only 27% of those aged 18-45 vaccinated. The survey also revealed significant differences between genders, age groups, and levels of knowledge about HPV, highlighting the need for targeted information and tailored co...

SourceUniversity of Zurich·JournalJAMA Network Open·TypeData/statistical analysis·DateMar 25, 2026

Engineered lipid nanoparticles reprogram immune metabolism for better mRNA vaccines

Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalNature Materials·TypeExperimental study·DateMar 17, 2026

ACP supports AAP’s evidence‑based childhood vaccine schedule

The American College of Physicians (ACP) supports the American Academy of Pediatrics' (AAP) 2026 childhood vaccine schedule, which is based on evidence and better reflects current disease epidemiology. The ACP's Immunization Committee found the AAP recommendations to be more evidence-based than the CDC's recommendations, particularly i...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateMar 16, 2026

Stark divide: Americans more confident in career scientists at US health agencies than leaders

A new survey from the Annenberg Public Policy Center finds that Americans are more confident in career scientists at federal health agencies such as the CDC, NIH, and FDA, than in their leaders. The survey also reveals a significant gap in confidence between career scientists and agency leaders, with only 5% of Americans expressing

ACP advises all adults 75 or older get a protein subunit RSV vaccine

The American College of Physicians advises all adults aged 75 or older to receive a protein subunit Respiratory Syncytial Virus (RSV) vaccine, reducing the risk of severe illness and hospitalization. Adults aged 60-74 with comorbid conditions may also consider receiving the vaccine. The benefits outweigh the harms in this age group.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeNews article·DateMar 2, 2026

Missed opportunity to protect pregnant women and newborns: Study shows low vaccination rates among expectant mothers in Norway against COVID-19 and influenza

A study of over 50,000 pregnant women in Norway found low vaccination rates against COVID-19 and influenza, with only 29.9% and 12.1% vaccinated respectively. The study highlights the need for targeted strategies to improve vaccination uptake among expectant mothers.

SourceEuropean Centre for Disease Prevention and Control (ECDC)·JournalEurosurveillance·TypeData/statistical analysis·DateFeb 19, 2026

Building immunity against avian flu risks

A team from UNIGE has shown that certain antibodies to seasonal flu can also target avian flu. Stimulating these antibodies could strengthen protection in the event of a pandemic. Vaccinated individuals show increased levels of cross-reactive antibodies capable of neutralizing the H5N1 virus, which may result in milder symptoms.

SourceUniversité de Genève·JournalNature Communications·TypeNews article·DateFeb 10, 2026

Massachusetts closest to eliminating cervical cancer, Southeastern states lag, new study finds

According to a new study, Massachusetts is close to eliminating cervical cancer due to its low incidence rate of 4.3 cases per 100,000 in recent years. In contrast, the Southeast and Southwest regions have higher rates of 11.2 and 9.9 cases per 100,000, respectively, making it challenging for these states to reach elimination goals.

SourceMedical University of South Carolina·JournalJNCI Cancer Spectrum·DateJan 26, 2026

Interim safety of RSVpreF vaccination during pregnancy

A recent study found that the RSVpreF vaccine does not pose a significant risk to pregnant women, providing reassurance for those who wish to be vaccinated. The interim report presents data from a large cohort of pregnancies with vaccine-seeking behavior, and results suggest no notable adverse effects.

SourceJAMA Network·JournalJAMA·DateJan 8, 2026

Whooping cough vaccination for pregnant women strengthens babies’ immune system

A study by Radboud University Medical Center found that pregnant women vaccinated against whooping cough transfer antibodies to their newborns, which provide long-lasting protection. This discovery supports the World Health Organization's recommendation to maintain whole-cell vaccines in low- and middle-income countries.

SourceRadboud University Medical Center·JournalThe Lancet Microbe·TypeRandomized controlled/clinical trial·DateJan 7, 2026

As measles cases rise, views of MMR vaccine safety and effectiveness -- and willingness to recommend it -- drop

A new survey by the Annenberg Public Policy Center finds a small but significant drop in the proportion of the public that would recommend getting the MMR vaccine, citing concerns over its safety and effectiveness. The survey also shows declines in perceived safety and effectiveness for other vaccines, such as seasonal flu and Covid-19.